IRCT20200623047902N22招募中未知
Bioequivalence study of Dasatinib 50mg tablet manufactured by Zistdaru Danesh versus Sprycel 50 mg in healthy volunteers in the fed and fasted condition
Zistdaru danesh Co.0 个研究点目标入组 48 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to dasatinib
研究者
相似试验
招募中
Unknown
Bioequivalence study of Dasatinib 100 mg tabletThis study is performed on healthy volunteers..IRCT20200105046010N81Actero Pharma Company24
招募中
不适用
In-vivo Bioequivalence Test of Dasatinib tablets with brand drug (SPRYCEL® 140 mg, Rosche, Switzerlandd)Plasma drug concentration.IRCT20200105046010N56anoalvand Pharmaceutical Co24
招募中
不适用
In-vivo Bioequivalence Test of Dasatonib tablet 100 mg Abidi Pharma with brand drug (SPRYCEL® 100 mg FC Tab, Bristol-Myers Squibb, UK)Bio equivalence test.IRCT20200105046010N66Abidi Pharmaceutical Company24
尚未招募
不适用
Study to compare efficacy & safety of Dasatinib with respect to Imatinib in newly diagnosed cases of chronic phase of chronic myeloid leukemia in terms of early response assessment at three months of therapyCTRI/2022/03/041208aiims rishikesh
已完成
1 期
A Bioequivalence Study of Dasatinib TabletLeukemia, Myelogenous, ChronicNCT05640804Chia Tai Tianqing Pharmaceutical Group Co., Ltd.56